Endo withdraws bid to add 'abuse deterrent' to Opana's label

Endo is putting the brakes on its bid to label its opioid pain med Opana ER "abuse deterrent."

On Friday, the Dublin drugmaker said it had decided to withdraw its supplemental new drug application related to the labeling, and it now plans to drum up and analyze more data surrounding the med. 

"We anticipate the generation of additional data and we will seek collaboration with FDA to appropriately advance Opana ER," Sue Hall, the company’s R&D head, said in a statement.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The move follows controversy surrounding the med and the role it played in last year’s HIV outbreak in southern Indiana. As the CDC and local officials determined, the outbreak resulted from addicts dissolving and injecting Opana ER--a possibility regulators warned Endo about in May of 2013.

While the new version of the drug, introduced in 2012, boasted special coating that supposedly made it more difficult to crush for snorting, the reformulation may have made the med easier to prepare for injection, the FDA found.

Endo isn’t the only company that’s raced to add abuse-deterrent properties to its opioid therapies--and it’s not the only company that’s run into problems marketing those properties. In June, the FDA dismissed an advisory committee recommendation and shot down an opioid pain candidate from KemPharm; while the panel had voted in favor of approval, they hadn’t deemed the prospect worthy of an “abuse deterrent” label.

Meanwhile, though, thanks to generic competition and an opioid market slowdown, Endo isn’t counting on sales contributions from Opana ER. Barclays analysts were also unimpressed by fellow branded meds Belbuca and Xiaflex, though, which didn’t put up big growth numbers to fill the void.

“We feel that the long-term growth profile is still in question,” they wrote in a note to clients.

- read the release 

Related Articles:
Endo keeps up its Valeant act with asset-sale talks
FDA overrides adcomm, shoots down KemPharm’s opioid
Abuse of Endo's second-generation Opana ER formulation implicated in Indiana HIV epidemic


Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.